Trials / Completed
CompletedNCT03907280
A Study in Healthy Men That Tests if Taking BI 1265162 by Mouth, Intravenously, or Inhaled Influences the Amount of BI 1265162 in the Blood
Absolute Bioavailability of BI 1265162 Following Oral and Inhaled Administration in Healthy Male Volunteers (an Open-label, Randomised, Single-dose, Three-period, Three-sequence Crossover Study Followed by a Fixed Treatment)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The main objective of this trial is to investigate the absolute bioavailability of BI 1265162 following administration of oral solution and inhaled (with and without charcoal) via Respimat.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 1265162 (T1) | oral solution |
| DRUG | BI 1265162 (T2) | Solution for inhalation |
| DRUG | BI 1265162 (R) | concentrate for i.v. solution |
| DRUG | BI 1265162 (T3) | Solution for inhalation |
Timeline
- Start date
- 2019-04-23
- Primary completion
- 2019-12-06
- Completion
- 2019-12-06
- First posted
- 2019-04-08
- Last updated
- 2022-07-06
- Results posted
- 2022-07-06
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT03907280. Inclusion in this directory is not an endorsement.